Antiangiogenic drugs such as Bevacizumab and Sunitinib that target VEGF and VEGFRs, respectively, have been successfully used to cure cancers; however, development of drug resistance after long-term administration is a common problem (Bergers and Hanahan, 2008; Lupo et al., 2016). The gene discussed is VEGFA; the disease is cancer.